
This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Analysis of Substituted Pyridine-C-Nucleosides by Direct Liquid Introduction Liquid Chromatography/Mass Spectrometry

E. L. Esmans^a; M. Belmans^a; I. Vrijens^a; Y. Luyten^a; F. C. Alderweireldt^a; L. L. Wotring^b; L. B. Townsend^b

^a University of Antwerp (R.U.C.A.), Laboratory for Organic Chemistry, Antwerp, Belgium ^b University of Michigan, College of Pharmacy, Ann Arbor, Michigan, U.S.A.

 $\label{eq:total continuous} \textbf{To cite this Article} \ Esmans, E. \ L. \ , Belmans, M. \ , Vrijens, I. \ , Luyten, Y. \ , Alderweireldt, F. \ C. \ , Wotring, L. \ L. \ and Townsend, L. B. (1987) 'Analysis of Substituted Pyridine-C-Nucleosides by Direct Liquid Introduction Liquid Chromatography/Mass Spectrometry', Nucleosides, Nucleotides and Nucleic Acids, 6: 5, 865 — 876$

To link to this Article: DOI: 10.1080/15257778708073433 URL: http://dx.doi.org/10.1080/15257778708073433

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ANALYSIS OF SUBSTITUTED PYRIDINE-C-NUCLEOSIDES BY DIRECT LIQUID INTRODUCTION LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY.

E.L. Esmans*, M. Belmans, I. Vrijens, Y. Luyten, F.C. Alderweireldt, L.L. Wotring¹ and L.B. Townsend¹. University of Antwerp (R.U.C.A.), Laboratory for Organic Chemistry, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.

¹University of Michigan, College of Pharmacy, Ann Arbor, Michigan (U.S.A.).

Abstract:

A method was elaborated for the analysis of a few original pyridine-C-nucleosides via microbore DLI/LC-MS. The compounds were analyzed on a 10RP8 column (25 cm x l mm) using a number of 0.01 M HCOONH₄/CH₃OH mixtures as eluant. Under appropriate LC-MS conditions, both α - and β -anomers were separated and identified. All nucleosides were characterized by the protonated molecular ion [MH]⁺, [B+30]⁺ and [B+44]⁺-fragment ions. Assignment of the α , β -configuration at C₁' was done with the aid of 13 C-NMR. From the DLI/LC-MS data, a semi-preparative HPLC-method was developed to purify the pyridine-C-nucleosides prior to biological evaluation.

I. Introduction.

In the past, high pressure liquid chromatography (HPLC) has emerged as a useful technique for the separation and purification of nucleosides 1.

Since the reliability of the biological data obtained for synthetic nucleoside analogs in different test systems (L-1210 mouse leukemia, coxsackievirus, poliovirus, e.g.) is highly dependent upon the purity of the compounds submitted, considerable effort has been expended in the development of sensitive and powerful analytical techniques. A technique which meets

the desired requirements is combined liquid chromatographymass spectrometry (LC-MS)^{2,3,4}.

In this paper, we wish to discuss the results of this technique for a series of substituted pyridine-C-nucleosides, which in turn is part of a programme aimed at the development of antitumor and/or antiviral drugs.

II. RESULTS AND DISCUSSION.

A series of substituted pyridine-C-nucleosides (I to XI) was synthesized using organo-lithium intermediates of pyridine derivatives and 2,4;3,5-di-O-benzylidene-D-ribose^{5,6,7}.

In order to obtain rapid and reliable information as well on structure as on purity, the crude reaction mixtures were investigated by DLI/LC-MS in a configuration described elsewhere³.

VII

 $\overline{\mathbf{XII}}$: R=CH₃; $\overline{\mathbf{IX}}$: R=C₂H₅; $\overline{\mathbf{X}}$: R=C₃H₇; $\overline{\mathbf{XI}}$: R=C₄H₉

Compounds I to VII were analyzed on a microbore 10RP8 column (25 cm x 1 mm I.D.) using 85% 0.01 M HCOONH $_4$ /15% CH $_3$ OH as the eluant, at a flow-rate of 80 μ L/min. A chromatogram, which can be considered representative for the analysis of compounds I to V, is depicted in FIG. 1. The data for the isomeric compounds I to IV are summarized in TABLE 1.

As can be seen in FIG. 1, 6-methyl-2-(D-ribofuranosyl)-pyridine (V) was located with the aid of the reconstructed ion chromatogram for the protonated molecular ion [MH]⁺ at m/z = 226. Because two chromatographic peaks, with respective retention times of 7.15 and 12.33 min, were found to respond at this m/z-value, it was concluded that the separation of the α -anomer from the β -anomer had been accomplished. The mass spectra of these compounds were all characterized by a protonated molecular ion [MH]⁺ which was in all cases the base peak. Also in both components the rearrangement ions at $[B+30]^+$ and $[B+44]^+$ were detected giving information about the structure of the base moiety (TABLE 1).

However, due to the simularities observed in the mass spectra of both anomers (FIGS. 2-3), an assignment of the absolute configuration (α or β) remained uncertain.

Therefore an experiment was set up separating a mixture of α - and β -adenosine under analogous conditions, followed by the injection of pure β -adenosine (FIG. 5).

From these results it could be concluded that α -adenosine had the lowest k'-value. This was an indication that in the series I-XI, the α -anomer would elute prior to the β -anomer. Furthermore, since in the ¹³C-NMR spectra, the signals of the carbon atoms of the α - and β -anomers could be unequivocally assigned, the ¹³C-NMR peak integration data could be compared to the corresponding chromatographic peak areas calculated from the LC-MS runs (TABLE 2). From these experiments there is no doubt that the α -anomer is the isomer with the lowest k'-value.

Together with the 6-methyl-C-nucleosides described above,




FIG. 1 : Microbore DLI/LC-MS of a crude mixture of 2-(D-ribofuranosyl)-6-methylpyridine (V). Eluant : 85% 0.01 M HCOONH $_4$ /15% CH $_3$ OH ; flow-rate : 80 μ L/min ; column : Microbore 10RP8 (25 cm x 1 mm I.D.). T $_{source}$ = 190°C ; T $_{desolvation\ chamber}$ = 210°C.




FIG. 2 : Mass spectrum of 2-(α -D-ribofuranosyl)-6-methylpyridine (RT = 7.15 min).

Downloaded At: 09:21 27 January 2011

TABLE 1 : DLI/IC-MS mass spectra of pyridine-C-nucleosides I to XI. ${\rm T_B = 190\,^{\circ}C,\ T_{DC} = 210\,^{\circ}C.\ Relative\ intensities\ are\ given}$ in parenthesis.

	Tu bareumests	•		
Compound	[MH] ⁺	[B+30] ⁺	[B+44] ⁺	Retention time (min)
α -I	212(100)	108(4)	122(5)	4.30
β - I	212(100)	108(2)	122(2)	6.30
α -II	226(100)	122(4)	136(4)	5.29
β-II	226(100)	122(4)	136(2)	14.29
α -III	226(100)	122(8)	136(11)	9.38
β -III	226(100)	122(9)	136(5)	15.34
α -IV	226(100)	122(4)	136(5)	8.53
β-IV	226(100)	122(4)	136(2)	13.18
α - V	226(100)	122(11)	136(12)	7.15
β − V	226(100)	122(8)	136(8)	12.33
α -VI	246(100)*	142(29)*	156(41)*	9.58
β-VI	246(100)*	142(21)*	156(42)*	11.37
α –VII	228(100)	124(35)	138(59)	2.50
β -VII	228(100)	124(17)	138(21)	3.23
VIII	242(100)	138(14)	152(19)	3.41
α -IX	256(100)	152(2)	166(2)	4.14
β -IX	256(100)	152(3)	166(4)	5.58
α - X	270(100)	166(12)	180(41)	5.53
β - X	270(100)	166(8)	180(10)	7.90
α - XI	284(100)	180(14)	194(23)	9.59
β-XI	284(100)	180(10)	194(12)	12.50

 $^{^{}ullet} \alpha$, eta -anomers not resolved.

 $^{^{\}star}$ relative intensity for $^{35}\text{Cl.}$





FIG. 3 : Mass spectrum of 2-(β -D-ribofuranosyl)-6-methylpyridine (RT = 12.33 min).



 $\underline{\rm FIG.~4}$: Mass spectrum of methanesulphonic acid (RT = 4.44 min ; m/z = 129 corresponds to [(CH_3SO_3H)(CH_3OH)(H)]^+-cluster.

TABLE 2: Comparison of ¹³C-NMR and LC-MS peak integration data.

LC-MS			13 _{C-NMR}		
	% α	% β	% α	€β	
I	38	62	42	58	
II	46	54	42	58	
III	44	56	46	54	
IV	44	56	44	56	
V	38	62	48	52	

impurities were eluted at, 4.44 min and 10.37 min respectively (FIG. 1).

The mass spectrum of the compound eluting at 4.44 min is depicted in FIG. 4. The ion at m/z=129 is clearly due to a $[(CH_3SO_3H)(CH_3OH)]H^+$ -cluster originating from methane sulfonic acid in the mixture. This impurity is liberated during the cyclisation process of the D-allo- and D-altromesylate precursors and is therefore present in all the crude reaction mixtures of C-nucleosides I to XI.

The other compound (RT = 10.37 min), characterized by a protonated molecular ion at [MH]⁺ = 110 was identified as 6-methyl-2-pyridone. This compound is probably generated during the synthesis of the 2-bromo-methylsubstituted pyridines from the corresponding 2-amino precursors via a Craig diazotation procedure. During such a procedure, 2-pyridones can emerge as by-products⁸.

The analysis of 4-(D-ribofuranosyl)-3-chloropyridine (VI) using the same chromatographic conditions, also resulted in the separation of the α - and β -anomers, eluting at 9.58 and 11.37 min respectively (FIG. 6). The corresponding mass spectra are given in TABLE 1.

These compounds were characterized by a protonated molecular ion [MH]⁺ at m/z = 246 (35 Cl) and [B+30]⁺-(m/z = 142, 35 Cl) and [B+44]⁺-ions (m/z = 156, 35 Cl). Also fragment ions at m/z = 218 (35 Cl) and 210 (35 Cl) were detected. These ions can be explained by the elimination of one and two molecules of H₂O from [MH]⁺ respectively (FIG. 7).




FIG. 5 : Microbore DLI/LC-MS of a mixture of α - and β -adenosine on a 10RP8 column (25 cm x 1 mm I.D.). Eluant : 85% 0.01 M HCOONH $_4$ /15% CH $_3$ OH. Flow-rate : 80 μ L/min. $T_{desolvation\ chamber} = 210^{\circ}\text{C}\ ;\ T_{source} = 190^{\circ}\text{C}.$




FIG. 6: Microbore DLI/IC-MS of a crude mixture of 4-(D-ribofuranosyl)-3-chloropyridine (VI). Eluant: 85% 0.01 M HCOONH $_4$ /15% CH $_3$ OH; flow-rate: 80 μ L/min. Column: microbore 10RP8 (25 cm x 1 mm I.D.). T $_{\rm source}$ = 190°C; T $_{\rm desolvation\ chamber}$ = 210°C.




FIG. 7 : Mass spectrum of 4-(α -D-ribofuranosyl)-4-chloropyridine (RT = 9.58 min).




FIG. 8 : Mass spectrum of 3-(β -D-ribofuranosyl)-2-pyridone.

The DLI/LC-MS investigation of a reaction mixture involving the synthesis of 2-fluoro-3-(D-ribofuranosyl)-pyridine were quite interesting and illustrate the power of LC-MS.

The mass spectra of the compounds eluting at 2.50 and 3.23 min respectively, were characterized by m/z-values of 228 ([MH]⁺), 124 ([B+30]⁺) and 138 ([B+44]⁺) (Fig. 8). These m/z-values differ by 2 amu from the values expected for the fluoro-compound. This would indicate that a substitution of the 2-fluoro-atom by a hydroxyl function had resulted in the formation of 3-(D-ribofuranosyl)-2-pyridone (VII). This reaction occurs during the last step of the general synthetic procedure, i.e. the cyclisation step in 1 N HCl. Later on, this substitution reaction was proven by the observation of carbonyl frequencies in the ¹³C-NMR spectrum at 160.11 and 158.3 ppm respectively.

The series of 2-(D-ribofuranosyl)-3-alkoxypyridines (VII to XI) showed a somewhat different chromatographic behaviour. The appropriate eluant composition was 60% 0.01 M $\rm HCOONH_4/40\%$ CH₃OH at a flow-rate of 80 $\rm \mu L/min$ (TABLE 1).

Under these conditions, the α - and the β -anomer of 3-methoxy-2-(D-ribofuranosyl)pyridine (VIII) were not resolved. A DLI/LC-MS run of XI is shown in FIG. 9.

Again in these compounds the base peak was the protonated molecular ion [MH]⁺, accompanied again by [B+30]⁺- and [B+44]⁺-ions. Together with the C-nucleosides, a small amount of methanesulfonic acid was detected.

From these DLI/LC-MS experiments, a strategy was deduced for the semi-preparative clean-up of the C-nucleosides prior to their biological evaluation. Since all impurities mentioned above were quite different in structure from the C-nucleosides I to IX, a purification method was used based upon affinity chromatography 4,6,9,10 followed by semi-preparative reverse phase chromatography using appropriate mixtures of 0.01 M HCOONH₄/CH₃OH⁷. The latter technique has allowed the biological evaluation of anomerically pure samples.




FIG. 9: DLI/LC-MS analysis of 3-butoxy-2-(D-ribofuranosyl)pyridine (XI). Eluant: 60% 1 M HCOONH $_4$ /40% CH $_3$ OH; flow-rate: 80 μ L/min; column: Microbore 10RP8 (25 cm x 1 mm I.D.). $T_{\text{Source}}: 190^{\circ}\text{C}, \ T_{\text{desolvation chamber}}: 210^{\circ}\text{C}.$

III. Experimental.

1. Products: CH₃OH (HPLC-grade) was purchased from Burdick and Jackson, HCOONH₄ from Janssen Chimica and α - and β -adenosine from Sigma.

2. LC-MS :

Aliquots of 1.5 μg were introduced on a microbore 10 RP8 column (25 cm x 1 mm I.D.) (1 μL internal loop). The flow rate was kept constant at 80 $\mu L/\min$ during all experiments. The DLI interface was cooled down to $-6^{\circ}C--8^{\circ}C$ with gaseous CO_2 and was coupled to a Riber 10-10B quadrupole mass spectrometer equipped with a SIDAR data system. During the liquid chromatographic/mass spectrometric experiments an ionization chamber and an ion source envelope pressure of respectively 0.6-0.8 mm Hg and 5×10^{-4} mm Hg was measured. The ionization energy was kept at 70 eV and the repeller voltage was 0 V. Primary ionization of the solvent was carried out with an emission current of 0.08 mA. The source temperature was 190°C and the temperature of the desolvation chamber was 210°C.

Acknowledgements.

The work is supported by NATO-grant 824/84.

References.

- 1. K.H. Schramm J.A. McCloskey in "GLC and HPLC determination of therapeutic agents", part III p.1149 Ed. M. Dekker Inc. (1979).
- 2. E.L. Esmans, Y. Luyten, F.C. Alderweireldt, Biomed. Mass Spectrom., 6, 347, (1983).
- 3. E.L. Esmans, P. Geboes, Y. Luyten, F.C. Alderweireldt, Biomed. Mass Spectrom., 12, 241 (1985).
- 4. E.L. Esmans, M. Belmans, Y. Vrijens, Y. Luyten, F.C. Alderweireldt, L.L. Wotring, L.B. Townsend, 34th Annual Conference on Mass Spectrometry and Allied Topics, 8-13 June 1986, Cincinatti (Ohio).
- M. Belmans, E. Esmans, R. Dommisse, J. Lepoivre
 F. Alderweireldt, J. Balzarini, E. De Clercq,
 Nucleos. & Nucleot., 4, 523 (1985).
- M. Belmans, Y. Vrijens, E.L. Esmans, J.A. Lepoivre,
 F.C. Alderweireldt, L. Townsend, L. Wotring,
 J. Balzarini, E. De Clercq, Nucleos. & Nucleot., 5,
 441 (1986).
- 7. Y. Vrijens, M. Belmans, E.L. Esmans, R. Dommisse, J.A. Lepoivre, F.C. Alderweireldt, L.L. Wotring L.B. Townsend in: "Proceedings of the 4th FECHEM Conference on Heterocycles in Bio-Organic Chemistry", p. 207. Ed. H.C. van der Plas, M. Simonyi, F.C. Alderweireldt, J.A. Lepoivre, Elsevier Amsterdam 1986.
- 8. L.C. Craig, Journ. Amer. Chem. Soc., <u>56</u>, 231 (1934).
- G.E. Davis, R.D. Suits, K.C. Kuo, C.W. Gehrke,
 T.P. Waalkes, E. Borek, Clin. Chem., 23, 1247 (1977).
- 10. M. Uziel, L.M. Smith, S.A. Taylor, Clin. Chem., 22, 1451 (1976).

Received January 19, 1987.